748186-99-4Relevant academic research and scientific papers
HIV PROTEASE INHIBITORS
-
Page/Page column 73, (2009/05/29)
Compounds of Formula I are disclosed: (I), wherein XA, k, R1, R2, R3, R4, R5, R5A, R6, R6A, R7 and R8 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Lysine sulfonamides as novel HIV-protease inhibitors: Nε-disubstituted ureas
Stranix, Brent R.,Sauve, Gilles,Bouzide, Abderrahim,Cote, Alexandre,Sevigny, Guy,Yelle, Jocelyn,Perron, Valerie
, p. 3971 - 3974 (2007/10/03)
A series of lysine sulfonamide analogues bearing a Nε-benzylic ureas was synthesized using both solution-phase and solid-phase approaches. A novel synthetic route of Nα-(alkyl)-Nα-(sulfonamides)lysinol using α-amino-caprolactam was developed. Evaluation of these novel protease inhibitors revealed compounds with high potency against wild-type HIV virus.
